Market Research Logo

Kidney Fibrosis - Pipeline Review, H2 2015

Kidney Fibrosis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Kidney Fibrosis - Pipeline Review, H2 2015’, provides an overview of the Kidney Fibrosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Kidney Fibrosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Kidney Fibrosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Kidney Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Kidney Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Kidney Fibrosis Overview
Therapeutics Development
Pipeline Products for Kidney Fibrosis - Overview
Pipeline Products for Kidney Fibrosis - Comparative Analysis
Kidney Fibrosis - Therapeutics under Development by Companies
Kidney Fibrosis - Therapeutics under Investigation by Universities/Institutes
Kidney Fibrosis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Kidney Fibrosis - Products under Development by Companies
Kidney Fibrosis - Products under Investigation by Universities/Institutes
Kidney Fibrosis - Companies Involved in Therapeutics Development
AbbVie Inc.
Angion Biomedica Corp.
Bio-inRen
BioLineRx, Ltd.
BiOrion Technologies B.V.
Cellmid Limited
Evotec AG
Galectin Therapeutics, Inc.
GenKyoTex S.A.
GNI Group Ltd.
Intercept Pharmaceuticals, Inc.
Isarna Therapeutics GmbH
Lpath, Inc.
MorphoSys AG
ProMetic Life Sciences Inc.
Raptor Pharmaceuticals Corp.
Regulus Therapeutics Inc.
SciFluor Life Sciences, LLC
Kidney Fibrosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ANG-3070 - Drug Profile Product Description
Mechanism of Action
R&D Progress
ANG-3586 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANG-4011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANG-4021 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BOT-191 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BRN-1889 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAB-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CGEN-856 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CT-140 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cysteamine DR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug to Inhibit Galectin-3 for Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Tissue Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
F-351 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GKT-136901 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GRMD-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ICG-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INT-767 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISTH-0047 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LJ-1888 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lpathomab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MOR-107 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PBI-4050 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PBI-4419 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Protein to Activate BMP-7 for Obesity, Osteoarthritis, Kidney Fibrosis and Alport Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR-339375 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit SphK2 for Oncology, Kideny Disease, Autoimmune Disorders, Fibrosis and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SOL-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kidney Fibrosis - Recent Pipeline Updates
Kidney Fibrosis - Dormant Projects
Kidney Fibrosis - Product Development Milestones
Featured News & Press Releases
Nov 12, 2015: Regulus Announces Grant of Patent Covering Lead microRNA Therapeutics
Nov 09, 2015: ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting
Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe
Oct 05, 2015: Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015
Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases
Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting
Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis
Nov 01, 2012: Prometic Life Sciences Presents Positive Data On New Anti-fibrotic Drug PBI-4419 At American Society Of Nephrology Annual Meeting
Oct 20, 2010: GNI Receives F351 Patent Allowance in Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Kidney Fibrosis, H2 2015
Number of Products under Development for Kidney Fibrosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Kidney Fibrosis - Pipeline by AbbVie Inc., H2 2015
Kidney Fibrosis - Pipeline by Angion Biomedica Corp., H2 2015
Kidney Fibrosis - Pipeline by Bio-inRen, H2 2015
Kidney Fibrosis - Pipeline by BioLineRx, Ltd., H2 2015
Kidney Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2015
Kidney Fibrosis - Pipeline by Cellmid Limited, H2 2015
Kidney Fibrosis - Pipeline by Evotec AG, H2 2015
Kidney Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2015
Kidney Fibrosis - Pipeline by GenKyoTex S.A., H2 2015
Kidney Fibrosis - Pipeline by GNI Group Ltd., H2 2015
Kidney Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2015
Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2015
Kidney Fibrosis - Pipeline by Lpath, Inc., H2 2015
Kidney Fibrosis - Pipeline by MorphoSys AG, H2 2015
Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2015
Kidney Fibrosis - Pipeline by Raptor Pharmaceuticals Corp., H2 2015
Kidney Fibrosis - Pipeline by Regulus Therapeutics Inc., H2 2015
Kidney Fibrosis - Pipeline by SciFluor Life Sciences, LLC, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Kidney Fibrosis Therapeutics - Recent Pipeline Updates, H2 2015
Kidney Fibrosis - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Kidney Fibrosis, H2 2015
Number of Products under Development for Kidney Fibrosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report